Molecular Subtype
Chronic Myeloid Leukemia, BCR-ABL1 Positive
CI-CAN-00002365CMLExplore in graph →
Hematologic102 active trials3 approved drugs320 evidence items
- NCIt
- C3174
- OncoTree
- CMLBCRABL1
- DOID
- 0081088
- DOID
- 8552
Loading cancer entity…
Loading cancer entity…
Molecular Subtype
CI-CAN-00002365CMLExplore in graph →
Variants & evidence
522 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|
| ABL1 F359V + ABL1 Fusion1 | |||||||
| Imatinib Mesylate + NilotinibSubstitutes | Predictive | C | Supports Resistance | 3 | accepted | EID6970In this open-label, phase II registration trial, patients that were imatinib-resistant or intolerant underwent nilotinib monotherapy. Within 12 months of nilotinib therapy, there was no significant di… (full text at CIViC) PMID 19652056 · Hughes et al., 2009 · Open in CIViC | civic |
| ABL1 F359V + ABL1 V299L + ABL1 Fusion1 | |||||||
| Axitinib | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID12319In an in vitro study, pro-B Ba/F3 cell line expressing a compound mutant of both V299L and F359V mutations in the ABL1 portion of the BCR-ABL1 fusion protein demonstrated increased sensitivity to axit… (full text at CIViC) PMID 26582647 · Zabriskie et al., 2016 · Open in CIViC | civic |
| ABL1 F486S + ABL1 Fusion7 | |||||||
| Axitinib | Predictive | D | Does Not Support Resistance | 2 | accepted | EID4438In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed similar incorporation when harboring fusions with the… (full text at CIViC) PMID 25686603 · Pemovska et al., 2015 · Open in CIViC | civic |
| Bosutinib | Predictive | C | Supports Resistance | 1 | accepted | EID4440This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chro… (full text at CIViC) PMID 22371878 · Khoury et al., 2012 · Open in CIViC | civic |
| Dasatinib | Predictive | B | Does Not Support Resistance | 3 | accepted | EID4571This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from … | |
| ABL1 G250E + ABL1 Fusion18 | |||||||
| Axitinib | Predictive | D | Supports Resistance | 2 | accepted | EID4320In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed higher incorporation when harboring fusions with the … (full text at CIViC) PMID 25686603 · Pemovska et al., 2015 · Open in CIViC | civic |
| 〃 | Predictive | D | Supports Resistance | 2 | accepted | EID4321In an in vitro study, pro-B Ba/F3 cell line expressing G250E mutation in the ABL1 portion of the BCR-ABL1 fusion protein (overexpression) demonstrated resistance to axitinib treatment (IC50: 1120.7nM)… (full text at CIViC) PMID 26582647 · Zabriskie et al., 2016 · Open in CIViC | civic |
| Bosutinib | Predictive | C | Does Not Support Resistance | 2 | accepted | EID4313In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and ma… | |
| ABL1 G398R + ABL1 Fusion3 | |||||||
| Bosutinib | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID4560In an in vitro study, a Ba/F3 murine cell line stably expressing the G398R mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to bosutinib treatment (IC50: 48.… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC | civic |
| Dasatinib | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID4561In an in vitro study, a Ba/F3 cell line stably expressing the G398R mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to dasatinib treatment (IC50: 1.27nM vs… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC | civic |
| Nilotinib | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID2864In an in vitro study, a Ba/F3 cell line stably expressing the G398R mutation in the ABL1 portion of the BCR-ABL1 gene fusion was associated with sensitivity to nilotinib treatment (IC50: 0.49-fold), c… | |
| ABL1 H396P + ABL1 Fusion7 | |||||||
| Axitinib | Predictive | D | Does Not Support Resistance | 2 | accepted | EID7770In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed lower incorporation when harboring fusions with the H… (full text at CIViC) PMID 25686603 · Pemovska et al., 2015 · Open in CIViC | civic |
| Bosutinib | Predictive | C | Does Not Support Resistance | 2 | accepted | EID4554In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and ma… (full text at CIViC) PMID 21865346 · Cortes et al., 2011 · Open in CIViC | civic |
| 〃 | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID4555In an in vitro study, a Ba/F3 murine cell line stably expressing the H396P mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with increased sensitivity to bosutinib treatment … | |
| ABL1 H396R + ABL1 Fusion13 | |||||||
| Axitinib | Predictive | D | Supports Resistance | 2 | accepted | EID4417In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed increased incorporation when harboring fusions with t… (full text at CIViC) PMID 25686603 · Pemovska et al., 2015 · Open in CIViC | civic |
| Bosutinib | Predictive | C | Supports Resistance | 1 | accepted | EID4410This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chro… (full text at CIViC) PMID 22371878 · Khoury et al., 2012 · Open in CIViC | civic |
| 〃 | Predictive | C | Does Not Support Resistance | 1 | accepted | EID4411In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and ma… | |
Data updated 5 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
PMID 19779040 · Müller et al., 2009 · Open in CIViC
| civic |
| 〃 | Predictive | D | Supports Resistance | 2 | submitted | EID4439In an in vitro study, a Ba/F3 cell line stably expressing the F486S mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with reduced sensitivity to dasatinib treatment (IC50: 5.… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC | civic |
| Imatinib | Predictive | C | Supports Resistance | 2 | accepted | EID8091In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. An accelerate-phase patient had a complete cytog… (full text at CIViC) PMID 12623848 · Branford et al., 2003 · Open in CIViC | civic |
| Imatinib Mesylate | Predictive | C | Supports Resistance | 1 | accepted | EID6987In a study of 39 chronic phase CML patients with BCR-ABL variants, F486S was seen in a single imatinib-resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. … (full text at CIViC) PMID 22371878 · Khoury et al., 2012 · Open in CIViC | civic |
| Nilotinib | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID2829In an in vitro study, a Ba/F3 cell line stably expressing the F486S mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to nilotinib treatment (IC50: 1.85-fold)… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC | civic |
PMID 21865346 · Cortes et al., 2011 · Open in CIViC
| civic |
| 〃 | Predictive | C | Supports Reduced Sensitivity | 2 | accepted | EID4314This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chro… (full text at CIViC) PMID 22371878 · Khoury et al., 2012 · Open in CIViC | civic |
| 〃 | Predictive | D | Supports Resistance | 2 | submitted | EID4312In an in vitro study, a Ba/F3 murine cell line stably expressing the G250E mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with reduced sensitivity to bosutinib treatment (I… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC | civic |
| Dasatinib | Predictive | B | Does Not Support Resistance | 3 | accepted | EID4316This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from … (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC | civic |
| 〃 | Predictive | C | Does Not Support Resistance | 3 | submitted | EID4319Prior to dasatinib treatment, two imatinib-resistant patients with chronic-phase chronic myeloid leukemia had the BCR-ABL1 fusion with G250E or G250E and G250E/F317L secondary variants in 10/10 or 9/1… (full text at CIViC) PMID 16775234 · Talpaz et al., 2006 · Open in CIViC | civic |
| 〃 | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID4317In a retrospective study of 174 imatinib-resistant or -intolerant Philadelphia chromosome BCR-ABL1 fusion positive accelerated phase chronic myeloid leukemia patients, patients with mutations in the A… (full text at CIViC) PMID 19487385 · Apperley et al., 2009 · Open in CIViC | civic |
| 〃 | Predictive | C | Supports Reduced Sensitivity | 1 | accepted | EID4318In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL m… (full text at CIViC) PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| 〃 | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID4315In an in vitro study, a Ba/F3 cell line expressing a G250E mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to dasatinib treatment (IC50: 1.8 nmol/L vs. 0.8 … (full text at CIViC) PMID 15930265 · O'Hare et al., 2005 · Open in CIViC | civic |
| Imatinib | Predictive | C | Supports Resistance | 3 | accepted | EID6993In a study of 39 chronic phase CML patients with BCR-ABL variants, G250E was seen in 6 imatinib-resistant patients that were also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine … (full text at CIViC) PMID 22371878 · Khoury et al., 2012 · Open in CIViC | civic |
| 〃 | Predictive | C | Supports Resistance | 2 | accepted | EID2646In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A late-chronic phase (CP) patient had a complete… (full text at CIViC) PMID 12623848 · Branford et al., 2003 · Open in CIViC | civic |
| 〃 | Predictive | D | Supports Resistance | 3 | accepted | EID2645A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL p… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC | civic |
| 〃 | Predictive | D | Supports Resistance | 2 | accepted | EID2647In two cell-based studies, a panel of either 18 or 16 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations … (full text at CIViC) PMID 15930265 · O'Hare et al., 2005 · Open in CIViC | civic |
| Imatinib Mesylate | Predictive | B | Supports Resistance | 1 | accepted | EID7041In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 9 had G250E mutations PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| 〃 | Predictive | D | Supports Resistance | 2 | accepted | EID6244In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were … (full text at CIViC) PMID 16772610 · Bradeen et al., 2006 · Open in CIViC | civic |
| Nilotinib | Predictive | D | Supports Resistance | 2 | accepted | EID2648In an in vitro study, a Ba/F3 cell line stably expressing the G250E mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to nilotinib treatment (IC50: 4.56-fold),… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC | civic |
| 〃 | Predictive | D | Supports Resistance | 2 | accepted | EID6267In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were … (full text at CIViC) PMID 16772610 · Bradeen et al., 2006 · Open in CIViC | civic |
PMID 19075254 · Redaelli et al., 2009 · Open in CIViC
| civic |
PMID 19075254 · Redaelli et al., 2009 · Open in CIViC
| civic |
| Dasatinib | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID4556In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC | civic |
| 〃 | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID4557In an in vitro study, a Ba/F3 cell line stably expressing the H396P mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to dasatinib treatment (IC50: 1.95nM vs.… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC | civic |
| 〃 | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID4558In an in vitro study, a Ba/F3 cell line expressing a H396P mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to dasatinib treatment (0.6 nmol/L vs. 0.8 nmol/L… (full text at CIViC) PMID 15930265 · O'Hare et al., 2005 · Open in CIViC | civic |
| Imatinib Mesylate + NilotinibCombination | Predictive | D | Supports Resistance | 2 | accepted | EID6240In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were … (full text at CIViC) PMID 16772610 · Bradeen et al., 2006 · Open in CIViC | civic |
PMID 21865346 · Cortes et al., 2011 · Open in CIViC
| civic |
| 〃 | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID4409In an in vitro study, a Ba/F3 murine cell line stably expressing the H396R mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to bosutinib treatment (IC50: 33.… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC | civic |
| Dasatinib | Predictive | B | Does Not Support Resistance | 3 | accepted | EID4413This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from … (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC | civic |
| 〃 | Predictive | C | Does Not Support Resistance | 3 | accepted | EID7823Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with H396R and E355G variants in 9/11 and 1/11 clones, respectively.… (full text at CIViC) PMID 16775234 · Talpaz et al., 2006 · Open in CIViC | civic |
| 〃 | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID4414In a retrospective study of 174 imatinib-resistant or -intolerant Philadelphia chromosome BCR-ABL1fusion positive accelerated phase chronic myeloid leukemia patients, patients with mutations in the AB… (full text at CIViC) PMID 19487385 · Apperley et al., 2009 · Open in CIViC | civic |
| 〃 | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID4415In a retrospective study of 84 imatinib-resistant or -intolerant Philadelphia chromosome BCR-ABL1 fusion positive (Ph+) chronic myeloid leukemia (in accelerated-phase or with blast crisis) or Ph+ acut… (full text at CIViC) PMID 16775234 · Talpaz et al., 2006 · Open in CIViC | civic |
| 〃 | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID4412In an in vitro study, a Ba/F3 cell line expressing a H396R mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to dasatinib treatment (1.3 nmol/L vs. 0.8 nmol/L… (full text at CIViC) PMID 15930265 · O'Hare et al., 2005 · Open in CIViC | civic |
| 〃 | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID4416In an in vitro study, a Ba/F3 cell line stably expressing the H396R mutation in the ABL1 portion of the BCR-ABL1 fusion protein was found to have increased sensitivity to dasatinib treatment, as compa… (full text at CIViC) PMID 15256671 · Shah et al., 2004 · Open in CIViC | civic |
| Imatinib | Predictive | C | Supports Resistance | 2 | accepted | EID2688In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. An accelerated-phase patient had a return to chr… (full text at CIViC) PMID 12623848 · Branford et al., 2003 · Open in CIViC | civic |
| 〃 | Predictive | D | Supports Resistance | 2 | accepted | EID2687A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL p… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC | civic |
| 〃 | Predictive | D | Supports Resistance | 2 | accepted | EID2689In two cell-based studies, a panel of either 18 or 16 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations … (full text at CIViC) PMID 15930265 · O'Hare et al., 2005 · Open in CIViC | civic |